Basic Organization Information
Susan G. Komen Breast Cancer Foundation, Inc., National Office
- Also Known As:
Susan G. Komen
- Physical Address:
- Web URL:
- NTEE Category:
G Disease, Disorders, Medical Disciplines
W Public, Society Benefit
H Medical Research
H30 Cancer Research
- Ruling Year:
- How This Organization Is Funded:
Susan G. Komen Race for the Cure(R) Series ($M) - $187
Susan G. Komen Breast Cancer 3 Day(R) Series ($M) - $90
Cause Marketing, Fundraising, Direct Mail ($M) - $174
Nancy G. Brinker promised her sister that she would do everything in her power to end breast cancer forever. That promise is now Susan G. Komen for the Cure®, the global leader of the breast cancer movement, having invested more than $2.2 billion since inception in 1982. As the world’s largest grassroots network of breast cancer survivors and activists, we’re working together to save lives, empower people, ensure quality care for all and energize science to find the cures. Thanks to events like the Susan G. Komen Race for the Cure® and the Susan G. Komen 3-Day for the Cure®, and generous contributions from our partners, sponsors and fellow supporters, we have become the largest source of nonprofit funds dedicated to the fight against breast cancer in the world.
Dr. Judith Salerno, M.D.
Before joining the IOM, Dr. Salerno was Deputy Director of the National Institute on Aging (NIA) at the National Institutes of Health, U.S. Department of Health and Human Services. She oversaw the Institute’s research into aging, including research on Alzheimer’s and other neurodegenerative diseases, frailty and function in late life, and the social, behavioral and demographic aspects of aging. As the NIA’s senior geriatrician, Dr. Salerno was vitally interested in improving the health and well-being of older persons, and designed public-private initiatives to address aging stereotypes, novel approaches to support training of new investigators in aging, and programs to communicate health and research advances to the public. Before joining the NIA in 2001, Dr. Salerno directed the continuum of Geriatrics and Extended Care programs across the nation for the U.S. Department of Veterans Affairs (VA), Washington, D.C. While at the VA, she launched widely recognized national initiatives for pain management and improving end-of-life care. Prior to this appointment, Dr. Salerno was Associate Chief of Staff at the VA Medical Center in Washington, D.C. where she developed and implemented innovative approaches to geriatric primary care and coordinated area-wide geriatric medicine training. Dr. Salerno also co-founded the Washington D.C. Area Geriatric Education Center Consortium, a collaboration of more than 160 educational and community organizations within the Baltimore-Washington region. A board-certified physician in internal medicine, Dr. Salerno earned her M.D. degree from Harvard Medical School in 1985 and a Master of Science degree in Health Policy from the Harvard School of Public Health in 1976.
Led by more than 100,000 survivors and activists, we are the world's largest and most progressive grassroots network fighting to end breast cancer forever. As the face and voice of the global breast cancer movement … We are local activists in more than 120 cities and communities, mobilizing more than 1.7 million friends and neighbors every year through events like the Susan G. Komen Race for the Cure® Series—the world's largest and most successful awareness and fundraising event for breast cancer. We are advocates at the local, state and federal level, fighting for the screening and treatment programs that save lives and the research that brings us closer to the cures. We are global citizens working with local health groups around the world and through our Web site, komen.org, to help millions of women in nearly 200 countries overcome the social, cultural and economic barriers to breast health and treatment.
Officers for Fiscal Year (IRS Form 990)
Highest Paid Employees & Their Compensation (IRS Form 990)
Research & Scientific Programs
- Population Served:
Poor/Economically Disadvantaged, Indigent, General
A significant portion of Komen research funding goes toward the new and exciting fields of cancer biology and genetics. Some Komen-sponsored programs already are making an impact for patients, and early results from other grants show potential for the development of future cures. Current treatments work best when breast cancer is detected early. Komen continues its investment into early detection, devoting research funds to the development of better screening methods and improving the precision and accuracy of existing screening tools. Komen works to ensure that all people, regardless of race, income, geographic location, or insurance status, have access to screening, and if diagnosed, to quality, effective treatment.
Program Long-Term Success:
Susan G. Komen funded research conducted by some of the earliest pioneers in targeted therapies. This includes early work in diagnosing HER 2 positive breast cancer and using the drug Herceptin to treat it.
Program Short-Term Success:
Program Success Monitored by:
Program Success Examples:
Contractor data is available for this organization!
Independent Contractor information for 2012, 2011, 2010, 2009, 2008 is available for this organization with a subscription to GuideStar Premium Pro.
GuideStar Premium Pro also includes:
- Comprehensive financial data, including functional expense detail, for every digitized fiscal year in GuideStar's database
- Ability to download up to 55 fields of data for up to 1,000 organizations at a time and up to five years worth of Income Statement
and Balance Sheet data for individual organizations
- Comprehensive advanced search capabilities, including criteria for functional expenses, investible assets, investment income
and audit & 990T filing requirements
- Ability to save organizations and searches for quick reference
- People search with salary range data
- Access to all available Forms 990
Since 1982, Komen for the Cure has played a critical role in every major advance in the fight against breast cancer – transforming how the world talks about and treats this disease and helping to turn millions of breast cancer patients into breast cancer survivors. We are proud of our contribution to some real victories:
More early detection – nearly 75 percent of women over 40 years old now receive regular mammograms, the single most effective tool for detecting breast cancer early (in 1982, less than 30 percent received a clinical exam).
More hope – the five-year survival rate for breast cancer, when caught early before it spreads beyond the breast, is now 98 percent (compared to 74 percent in 1982).
More research – the federal government now devotes more than $900 million each year to breast cancer research, treatment and prevention (compared to $30 million in 1982).
More survivors – America’s 2.5 million breast cancers survivors, the largest group of cancer survivors in the U.S., are a living testament to the power of society and science to save lives.
For more in-depth information about this organization's impact, view their Charting Impact Report
Expert Reviews and Comments
Evidence of Impact
The Susan G. Komen Breast Cancer Foundation has had a strong impact by bringing breast cancer issues to light and raising valuable funds for breast cancer research.
According to experts, this organization's greatest strengths are its decisions on funding research for a cure and its strong marketing tactics.
Areas for Improvement
The major sources of criticism for the Susan G. Komen Breast Cancer Foundation are in the organization's lack of collaborations and its need for new fresh ideas.